Your browser is no longer supported. Please, upgrade your browser.
Global Blood Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.04 Insider Own1.90% Shs Outstand62.10M Perf Week-4.74%
Market Cap1.74B Forward P/E- EPS next Y-3.03 Insider Trans-0.18% Shs Float55.70M Perf Month-21.96%
Income-249.50M PEG- EPS next Q-1.19 Inst Own- Short Float21.85% Perf Quarter-32.98%
Sales148.70M P/S11.69 EPS this Y11.80% Inst Trans4.97% Short Ratio10.52 Perf Half Y-45.47%
Book/sh5.85 P/B4.67 EPS next Y34.90% ROA-35.80% Target Price- Perf Year-60.68%
Cash/sh7.58 P/C3.61 EPS next 5Y37.00% ROE-57.60% 52W Range27.10 - 71.23 Perf YTD-36.90%
Dividend- P/FCF- EPS past 5Y-0.50% ROI-43.00% 52W High-61.63% Beta0.99
Dividend %- Quick Ratio8.70 Sales past 5Y- Gross Margin98.40% 52W Low0.85% ATR1.44
Employees389 Current Ratio9.50 Sales Q/Q176.60% Oper. Margin- RSI (14)26.40 Volatility3.79% 4.46%
OptionableYes Debt/Eq0.41 EPS Q/Q-0.40% Profit Margin- Rel Volume0.91 Prev Close27.93
ShortableYes LT Debt/Eq0.41 EarningsAug 03 AMC Payout- Avg Volume1.16M Price27.33
Recom2.00 SMA20-14.07% SMA50-22.76% SMA200-36.22% Volume1,055,581 Change-2.15%
Jun-28-21Downgrade JP Morgan Overweight → Neutral $70 → $36
Apr-14-21Initiated SVB Leerink Outperform $54
Mar-12-21Initiated Wolfe Research Outperform $67
Feb-25-21Downgrade William Blair Outperform → Mkt Perform
Jan-20-21Downgrade Piper Sandler Overweight → Neutral $75 → $50
Dec-15-20Resumed H.C. Wainwright Buy $75
Dec-03-20Initiated RBC Capital Mkts Outperform $75
Nov-06-20Downgrade Raymond James Outperform → Mkt Perform
Oct-06-20Initiated Evercore ISI Outperform $102
Aug-25-20Initiated Raymond James Outperform $115
Jul-20-20Initiated ROTH Capital Buy $129
Jul-13-20Initiated BofA Securities Buy $92
Jul-01-20Upgrade Goldman Neutral → Buy $91 → $103
Apr-28-20Initiated Stifel Buy $112
Jan-31-20Downgrade SunTrust Buy → Hold $110 → $75
Nov-25-19Resumed Cantor Fitzgerald Overweight $110 → $98
Nov-06-19Initiated Canaccord Genuity Hold $50
May-29-19Resumed Goldman Neutral
Dec-03-18Reiterated H.C. Wainwright Buy $125 → $150
Aug-06-18Initiated Piper Jaffray Overweight $80
Jul-27-21 08:00AM  
Jul-22-21 10:02AM  
Jul-21-21 11:52AM  
Jul-09-21 08:00AM  
Jul-01-21 07:59AM  
Jun-29-21 11:13AM  
Jun-15-21 08:00AM  
Jun-14-21 07:00AM  
Jun-11-21 03:05AM  
Jun-08-21 03:42AM  
Jun-04-21 11:31AM  
Jun-01-21 08:00AM  
May-12-21 10:00AM  
May-07-21 08:00AM  
May-06-21 03:03PM  
May-05-21 05:45PM  
May-04-21 08:00AM  
Apr-28-21 12:33PM  
Apr-20-21 10:13AM  
Apr-09-21 03:28AM  
Apr-08-21 07:20AM  
Apr-05-21 08:00AM  
Apr-04-21 05:18AM  
Mar-26-21 11:30AM  
Mar-18-21 07:00AM  
Mar-16-21 07:00AM  
Mar-08-21 08:00AM  
Mar-04-21 04:28PM  
Mar-02-21 08:00AM  
Feb-25-21 04:01AM  
Feb-24-21 04:44PM  
Feb-23-21 10:28AM  
Feb-19-21 08:00AM  
Feb-17-21 08:00AM  
Feb-08-21 01:02AM  
Feb-05-21 08:00AM  
Feb-04-21 08:00AM  
Jan-28-21 10:12AM  
Jan-27-21 07:00AM  
Jan-07-21 08:00AM  
Jan-06-21 08:13AM  
Jan-05-21 08:00AM  
Dec-25-20 01:54AM  
Dec-16-20 10:25AM  
Dec-15-20 08:13AM  
Dec-07-20 08:00AM  
Dec-06-20 10:00AM  
Dec-05-20 11:32AM  
Dec-03-20 09:56AM  
Dec-02-20 07:00AM  
Nov-25-20 08:00AM  
Nov-13-20 08:45AM  
Nov-10-20 06:04AM  
Nov-09-20 08:00AM  
Nov-07-20 09:38AM  
Nov-06-20 12:13PM  
Nov-05-20 06:25PM  
Nov-04-20 03:11PM  
Nov-02-20 08:11AM  
Oct-29-20 08:00AM  
Oct-26-20 06:00AM  
Oct-12-20 08:00AM  
Oct-05-20 08:00AM  
Sep-18-20 11:31AM  
Sep-17-20 09:48AM  
Sep-15-20 12:43AM  
Sep-09-20 08:00AM  
Sep-08-20 04:05PM  
Sep-04-20 11:31AM  
Sep-03-20 08:00AM  
Aug-26-20 10:44PM  
Aug-25-20 11:39AM  
Aug-07-20 08:00AM  
Aug-05-20 05:35PM  
Aug-03-20 12:54PM  
Jul-30-20 08:00AM  
Jul-29-20 08:00AM  
Jul-25-20 09:10AM  
Jul-17-20 12:45PM  
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Svoronos DawnDirectorJun 18Sale36.541,60958,7933,684Jun 21 04:31 PM
Pizzo Philip A.DirectorJun 18Sale36.541,06538,9156,772Jun 21 04:15 PM
Fink EricChief Human Resources OfficerMay 10Buy37.9650018,9805,161May 10 05:38 PM
Fink EricChief Human Resources OfficerOct 05Sale60.004,532271,9200Oct 07 05:12 PM
PIERCE GLENNDirectorSep 10Option Exercise15.0315,000225,45019,800Sep 14 06:12 PM
CATHERS BRIAN EDWINChief Scientific OfficerAug 20Sale63.772,200140,2945,244Aug 24 05:14 PM
Fink EricChief Human Resources OfficerAug 05Sale69.622,454170,8510Aug 07 04:09 PM